The endogenous cannabinoids 2-arachidonoylglycerol (2-AG) and anandamide (AEA) play vital roles during nervous system development. The degradation of 2-AG and AEA is mediated by monoacylglycerol lipase (MAGL) and fatty acid amide hydrolase (FAAH), respectively. These enzymes are inhibited following developmental chlorpyrifos (CPF) exposure. To investigate whether this inhibition is persistent or whether accumulation of endocannabinoids in the brain occurs, 10-day-old rat pups were orally exposed daily for 7 days to either corn oil or increasing dosages of CPF (1, 2.5, or 5 mg/kg), and forebrains were collected at 4, 12, 24, and 48 h following the last administration. All dosages inhibited cholinesterase (ChE), FAAH, and MAGL, and elevated AEA and 2-AG levels with the greatest effect occurring at 12 h with ChE, FAAH, AEA, and 2-AG and at 4 h with MAGL. With the high dosage, return to control levels occurred with 2-AG (48 h) only. With the medium dosage, return to control levels occurred with MAGL, 2-AG, and AEA (48 h) but not with ChE or FAAH. With the low dosage, return to control levels occurred with MAGL (12 h), ChE and 2-AG (24 h), and AEA (48 h) but not with FAAH. With the lowest dosage, peak inhibition of FAAH (52%) is greater than that of ChE (24%) and that level of FAAH inhibition is sufficient to induce a persistent pattern of elevated AEA. It is possible that this pattern of elevation could alter the appropriate development of neuronal brain circuits.
Although the elimination of the household uses of the organophosphate (OP) insecticide chlorpyrifos (CPF) in 2000 reduced the amount introduced into the environment, CPF remains the second most widely used insecticide in the United States based on the most recent analysis of use in 2007 (Grube et al., 2011) . It has been reported that children living in agricultural communities continue to be at risk for exposure to CPF and other OP insecticides (Koch et al., 2002) . Developmental exposure to OP insecticides has been suggested to have lasting negative impacts including decreased cognitive abilities and motor skills (Bouchard et al., 2011; Engel et al., 2011; Ruckart et al., 2004) . Specifically, children exposed to CPF exhibit increased manifestation of attention disorder and attention-deficit/hyperactivity disorder problems (Rauh et al., 2006) , decreased working memory and IQ (Rauh et al., 2011) , and had altered brain morphology (Rauh et al., 2012) .
The traditional toxicological target for CPF, as with other OP insecticides, is the inhibition of acetylcholinesterase (ChE, acetylcholine [ACh] hydrolase, EC 3.1.1.7), a serine esterase that degrades the widely distributed neurotransmitter ACh. Significant inhibition of ChE activity leads to accumulation of ACh and hyperactivity of the cholinergic system, resulting in the disruption of normal physiological functioning. Because the developing nervous system is in the process of maturing and establishing the correct pathways and synapses, exposure to a neurotoxicant during that period could alter the appropriate establishment of neurological pathways and disrupt mental development. Typically, the environmental levels of CPF would not be high enough to induce significant inhibition of ChE in the brain. However, in laboratory studies, neurochemical and behavioral effects have been observed following exposure to levels of CPF and other OP insecticides that induce only minimal amounts of ChE inhibition and little hyperactivity in the cholinergic system (Levin et al., 2002; Slotkin et al., 2006 Timofeeva et al., 2008a, b) . This has led to the hypothesis that the developmental toxicological effects of OP insecticides involve a currently unknown "noncholinergic mechanism of action."
One system that could qualify it as a potential "noncholinergic mechanism of action" with respect to developmental OP insecticide toxicity is the endocannabinoid system. The endocannabinoid system plays a pivotal role in normal brain development (for reviews, see Anavi-Goffer and Mulder, 2009; Harkany et al., 2008) , suggesting that disruption of its function during development could lead to deleterious effects.
Endocannabinoids are lipid mediators that are synthesized on demand in an activity-dependent manner and are not stored in vesicles due to their lipophilic nature (Di Marzo et al., 1994) . The two main endocannabinoids are arachidonoylethanolamide (AEA or anandamide) and 2-arachidonoylglycerol (2-AG) (Devane et al., 1992; Di Marzo et al., 1994; Mechoulam et al., 1995; Sugiura et al., 1995; Stella et al., 1997) . 2-AG is degraded in the central nervous system (CNS) primarily by the action of monoacylglycerol lipase (MAGL) although other enzymes have been reported to contribute to its hydrolysis in the CNS (Blankman et al., 2007) and in immune cells (Xie et al., 2010) . AEA is degraded by the action of fatty acid amide hydrolase (FAAH), but FAAH has also been reported to degrade 2-AG in vitro.
Previously, acute exposure of adult mice to OP compounds (Quistad et al., 2001 (Quistad et al., , 2002 (Quistad et al., , 2006 resulted in the inhibition of 2-AG and AEA hydrolysis in the brain. More recently, we reported that following repeated developmental exposure to CPF, the hydrolysis of 2-AG and AEA in the brain was inhibited in a dose-related manner, and the extent of inhibition from highest to lowest level was AEA hydrolysis > ACh hydrolysis > 2-AG hydrolysis (Carr et al., 2011) . Although the greater sensitivity of AEA hydrolysis activity compared with ChE activity suggests that inhibition of AEA metabolism may be a mechanistic target following developmental OP exposure, several issues require clarification. Our previous data (Carr et al., 2011) were obtained at a single time point (4 h) following exposure. Thus, information about the persistence of inhibition of AEA hydrolysis in the brain following developmental OP exposure is not known. Transient inhibition may be less likely to exert long-lasting effects than would persistent inhibition. In addition, it is not known if the inhibition of AEA hydrolysis by developmental OP exposure results in accumulation of endocannabinoids. Previous studies have reported that the inhibition of FAAH and MAGL activity in adult mice exposed to a single high dosage of CPF results in increased levels of 2-AG and AEA in the brain (Nomura and Casida, 2011; Nomura et al., 2008) . However, it is not clear whether a similar situation exists in developing rats exposed to lower levels of CPF. The goal of the current study was to continue investigations in this area by determining the pattern of inhibition and recovery of 2-AG and AEA hydrolysis and whether levels of 2-AG and AEA in the brain of developing rats are elevated following repeated exposure to different dosages of CPF.
MATErIALs And METHods
Chemicals. CPF (> 99% purity) was a generous gift from DowElanco Chemical Company (Indianapolis, IN). DowElanco did not contribute to or have any control over the data presented in this publication. All other chemicals were purchased from Cayman Chemicals (Ann Arbor, MI) or Sigma Chemical Co. (St Louis, MO).
Animal treatment. Adult male and female Sprague Dawley rats were obtained from Harlan Laboratories (Prattville, AL) and used for breeding. All animals were housed in a temperature-controlled environment (22 ± 2°C) with a 12-h dark-light cycle with lights on between 0700 and 1900 h in an Association for Assessment and Accreditation of Laboratory Animal Care-accredited facility. LabDiet rodent chow and tap water were freely available during the experimentation. All procedures were approved by the Mississippi State University Institutional Animal Care and Use Committee. Following parturition, male and female rat pups within the same litter were assigned to different treatment groups. There was always a representative control animal of the same sex present in each litter for each set of the three CPF-treated animals. The day of birth was considered as postnatal day 0 (PND0).
CPF was dissolved in corn oil and administered at a volume of 1 ml/kg body weight by oral gavage (per os) every day from PND10 through PND16. This period would correspond to the period following birth in humans. This age range is beyond the period of the brain growth spurt (PND7 and below) but encompasses a time of significant brain maturation (Andersen, 2003; Counotte et al., 2011; Tau and Peterson, 2010) . Oral gavage was performed using a 50-μl tuberculin syringe equipped with a 1-inch 24-gauge straight intubation needle (Popper and Sons, Inc., New Hyde Park, NY) to deliver the solution to the back of the throat. The dosages selected were 1 mg/kg (low), 2.5 mg/kg (medium), and 5 mg/kg (high). The latter dosage (5 mg/kg) was previously used in other developmental studies involving CPF (Aldridge et al., 2004 (Aldridge et al., , 2005a Auman et al., 2000; Dam et al., 1999 Dam et al., , 2000 Dam et al., , 2003 Meyer et al., 2004a Meyer et al., , b, 2005 although those studies utilized a different administration route (sc) and vehicle (dimethyl sulfoxide), which yields greater ChE inhibition than does our route and vehicle (Carr and Nail, 2008) .
The dosages used in this study were designed to induce inhibition of ChE activity in order to further understand the potential risk of exposure in children to OP insecticides. These dosages are above the oral repeated No Observed Effect Level (NOEL) for inhibition of brain ChE activity (0.75 mg/kg) but below the oral repeated NOEL for signs of toxicity (4.5 mg/kg) for postnatal rats as reported by Zheng et al. (2000) . However, it is unclear whether these dosages recapitulate the exposure levels in children. Previous studies have used dosages as high as 5 mg/kg and claimed that this dosage falls within the range of estimated fetal and neonatal exposures from environmental exposure or home use of CPF (Aldridge et al., 2005b) . Most likely, CPF exposure in children will occur at levels lower than those used in this study with the exception of situations of high levels of contamination.
Rat pups were sacrificed at 4, 12, 24, and 48 h after the last exposure to CPF. Immediately prior to sacrifice, rats were anesthetized using CO 2 followed by decapitation. Brains were rapidly removed and dissected on ice to obtain the forebrain (excluding the medulla and cerebellum). The forebrain was split into left and right hemispheres that were frozen on a stainless steel plate on top of dry ice and maintained at −80°C until assay. Handling, sacrifice, and dissection were performed by the same person to ensure similar processing times between individual rats. The average time between decapitation and freezing of the tissues was less than 90 s.
Enzyme assays. One forebrain hemisphere was homogenized at 200 mg tissue weight/ml of cold 0.05M Tris-HCl buffer containing 0.2mM EDTA (pH 7.4 at 37°C) in a glass mortar using a Wheaton motorized tissue grinder and a Teflon pestle. For determination of ChE activity, an aliquot was diluted in cold 0.05M Tris-HCl buffer (pH 7.4 at 37°C) to 40 mg tissue/ml. Following further dilution to 1 mg tissue/ml (final concentration), the activity of forebrain ChE was measured spectrophotometrically using a modification (Chambers et al., 1988) of Ellman et al. (1961) with acetylthiocholine as the substrate (1mM final concentration) and 5,5′-dithiobis(nitrobenzoic acid) as the chromogen.
An additional 1.0-ml aliquot of the 200 mg/ml homogenate was centrifuged at 1500 × g for 10 min to obtain supernatant, which was diluted threefold for determination of AEA and 2-AG hydrolysis at 37°C. Following a 10-min preincubation period, AEA and 2-AG hydrolysis in forebrain (2.667 mg tissue/ml final concentration) were determined by incubation with substrate (either 50μM AEA or 2-AG) for 10 min. The reaction was terminated by the addition of four volumes of cold acetonitrile containing 2.5μM of internal standard (arachidonic acid-d 8 ). Samples were placed in ice for 10 min and centrifuged at 21,000 × g for 10 min to obtain supernatant. The amount of arachidonic acid formed was determined by liquid chromatography-mass spectrometry (Xie et al., 2010) . For determination of MAGL and FAAH activity, corresponding tubes containing either 10μM of the specific MAGL inhibitor 4-nitrophenyl-4-(dibenzo [d] [1,3]dioxol-5-yl(hydroxy)methyl)piperidine-1-carboxylate (JZL184) or of the specific FAAH inhibitor (3′-(aminocarbonyl)[1,1′-biphenyl]-3-yl)-cyclohexylcarbamate (URB597), respectively, were included during the preincubation period prior to adding substrate.
Protein concentrations of tissue extracts were quantified with the Folin phenol reagent using bovine serum albumin as a standard (Lowry et al., 1951) . Specific activities were calculated as nano mole (ChE) or pica mole (FAAH or MAGL) product produced per minute milligram protein.
Endocannabinoid analysis. The remaining forebrain hemisphere was dounce homogenized in 2:2:1 vol/vol/vol ethyl acetate:hexane:0.1M potassium phosphate (pH 7.0) (total volume, 5 ml) containing known amounts of deuterated internal standards (2-AGd 8 and AEA-d 4 ). The emulsion was vortexed (1 min) and centrifuged (1400 × g, 10 min); the top organic layer was removed and dried under a stream of N 2 ; and the residue was resolubilized in 1:1 vol/vol water:methanol (200 μl). After filtration through centrifugal filters (0.1 μm), a 10-μl aliquot of the resolubilized lipid was injected onto an Acquity UPLC BEH C18 column (2.1 × 100 mm, 1.7 μm), equipped with precolumn (2.1 × 5 mm, 1.7 μm), and interfaced with a Thermo Quantum Access triple-quadrupole mass spectrometer. The mobile phase was a blend of solvent A (2mM ammonium acetate/0.1% acetic acid in water) and solvent B (0.1% acetic acid in methanol). Analytes were eluted with the following gradient program: 0 min (95% A, 5% B), 0.5 min (95% A, 5% B), 5 min (5% A, 95% B), 6 min (5% A, 95% B), 7 min (95% A, 5% B), and 8 min (95% A, 5% B). Flow rate was 0.4 ml/min, and the entire column eluate is directed into the mass spectrometer (heated electrospray ionization in positive ion mode + m/z 352 > 66. Scan times were 0.2 s/SRM, and scan width was 0.01 m/z. Collision energies and tube lens voltage were optimized using autotune software for each analyte by postcolumn infusion of individual compounds into 50% A/50% B mobile phase, pumping at a flow rate 0.4 ml/min. The source settings were as follows: spray voltage, +4000 V; vaporizer temperature, 350°C; capillary temperature, 285°C; sheath gas pressure, 50 psi; auxiliary gas pressure, 5 psi. Endocannabinoids are quantified by measuring the area under each chromatographic peak and comparing it to the area under the chromatographic peak for the appropriate deuterated internal standard, followed by correction for the ionization efficiency of 2-AG and AEA relative to their deuterated standards (empirically determined). 2-AG is known to rapidly isomerize to 1(3)-AG, yielding a mixture of the two compounds. Therefore, chromatographic peaks for 2-AG and 1(3)-AG were integrated together and summed. The endocannabinoid amounts are normalized on the brain wet weight and expressed as pmol/g brain (AEA) or nmol/g brain (2-AG).
Statistical analysis. All statistical analyses was performed using the SAS statistical package (SAS Institute, 2009 ). Enzyme activity data and endocannabinoid data were tested using Shapiro-Wilk's test to check the normality of the residuals and homoscedasticity of data. Data were log transformed where appropriate. Data were also tested for outliers using the modified Z-score (Iglewicz and Hoaglin, 1993) , PROC BOXPLOT, and four PROC ROBUSTREG tests using each of the four estimations available (M, LTS, S, and MM). Data points identified as outliers in all six tests were removed from the data set. Data were analyzed using the PROC MIXED procedure (Littell et al., 1996) . For this model, treatment, time, and sex were considered as fixed effects, and litter was treated as random effect. The model identified significant differences between sexes, times, and treatments and all possible interactions. In the initial overall analysis, there were no significant sex differences or significant sex × treatment or sex × treatment × time interactions for either the enzyme activities or the endocannabinoid levels. Thus, males and females were pooled for mean separation, which was performed by least significant difference. The criterion for significance was set at p ≤ 0.05.
rEsuLTs
No signs of overt toxicity or cholinergic hyperstimulation, such as lacrimation, diarrhea, or tremors, were observed following CPF exposure. The effect on weight gain was similar to that reported earlier (Carr et al., 2011) with no effects at the low dosage and decreased weight gain throughout the study with the high dosage and toward the end of the treatment period with the medium dosage (Supplementary figures) .
With respect to forebrain ChE activity levels, there was a significant overall effect of treatment (p < 0.0001) and time (p < 0.0033) and a significant treatment × time interaction (p < 0.0001). Mean separation was performed on the significant treatment × time interaction. Significant ChE inhibition was observed in all three dosage groups at 4 and 12 h and in the medium and high dosages at 24 and 48 h after the last administration of CPF (Fig. 1 ). There were no significant differences in control values at the different sampling times. Peak inhibition occurred at 12 h with all three dosages with 24, 55, and 68% inhibition at the low, medium, and high dosages, respectively. Although there were no significant differences in activity at the different sampling times with the low dosage, significant recovery of activity was observed by 48 h with the medium and high dosages.
With respect to forebrain MAGL activity levels, there was a significant overall effect of treatment (p < 0.0001) and a significant sex × time interaction (p = 0.0014) but no significant interactions involving treatment. The lack of a significant treatment × time interaction indicates that MAGL activity within each treatment group does not recover significantly within the 48 h following cessation of exposure. Although the overall analysis indicated that treatment was significantly different from control, these results did not allow us to determine whether a treatment group was significantly different from its corresponding control group with a specific time. Therefore, to better demonstrate the impact of treatment at each time, a lower level analysis for each sampling time was performed followed by means separation to identify differences between each treatment group and its corresponding control at each time. Significant MAGL inhibition was observed in the low dosage at 4 h only, in the medium dosage at 4, 12, and 24 h, and in the high dosage throughout the study (Fig. 2) . Peak inhibition appeared to occur by 4 h with 14, 24, and 41% inhibition at the low, medium, and high dosages, respectively, with no statistical significant recovery thereafter.
With respect to forebrain FAAH activity levels, there was a significant overall effect of treatment (p < 0.0001) and time (p < 0.0001) and a significant treatment × time interaction (p < 0.0001). Mean separation was performed on the significant treatment × time interaction. There were no significant differences in control values at the different sampling times. Significant FAAH inhibition was observed in all three dosage groups at all sampling times (Fig. 3) . In the low-dosage group, peak inhibition (53%) was present at 12 h with significant recovery observed by 24 h. In the medium-and high-dosage groups, peak inhibition (90-94%) occurred at 4-12 h, but significant recovery was observed by 24 h although substantial inhibition was still present.
With respect to forebrain 2-AG levels, there was a significant overall effect of treatment only (p < 0.0004). The lack of a significant treatment × time interaction suggests that the elevated 2-AG levels do not decrease significantly within the 48 h following cessation of exposure. Although the overall analysis indicated that treatment was significantly different from control, these results did not allow us to determine whether a treatment group was significantly different from its corresponding control group with a specific time. Therefore, to better demonstrate the impact of treatment at each time, a lower level analysis for each sampling time was performed followed by means separation to identify differences between each treatment group and its corresponding control at each time. For 4, 12, and 24 h, there was a significant effect of treatment but no significant sex effects or sex × treatment interaction. However, there was no significant difference at 48 h. With the high dosage of CPF, the level of 2-AG was significantly elevated at 4, 12, and 24 h with highest levels (61-63% above control) occurring between 4 and 12 h (Fig. 4) . The level of 2-AG was also significantly elevated (52%) at 12 h with the medium dosage. Exposure to the low dosage significantly increased the level of 2-AG at 12 h, but no significant differences from control values were observed at any other time.
With respect to AEA levels, there was a significant overall effect of treatment (p < 0.0001) and time (p < 0.0062) and a significant treatment × time interaction (p < 0.00342). There was also a significant sex × time interaction (p = 0.0014) but no significant interactions involving treatment. Mean separation was performed on the significant treatment × time interaction. There were no significant differences in control values at the different sampling times. In the low-dosage group, significant elevation of AEA was present at 12 h (65%) and 24 h (43%) with no statistically significant differences between sampling times (Fig. 5) . In the medium-dosage group, peak elevation of AEA occurred at 12 h (128%) with a decrease by 24 h (56%). By 48 h, AEA levels in the medium dosage remained elevated but not statistically significant. In the high-dosage group, AEA was significantly elevated at all times sampled with peak levels (190%) occurring at 12 h (Fig. 5 ) with significant recovery occurring by 24 h (51%). At 48 h, the percent increase above control of AEA levels in the high dosage was numerically greater than that observed at 24 h, but the two values were not statistically different.
FIG. 3.
Specific activity of FAAH in the forebrain of rat pups exposed daily from PND10 through PND16 to either corn oil (control) or 1.0, 2.5, or 5.0 mg/ kg CPF. Values are expressed as pmole product/min mg protein ± SE (n = 6-8). Percent inhibition for each treatment group compared with its respective control is presented in the oval overlaying the corresponding bar. Bars indicated with an asterisk (*) are statistically significant (p ≤ 0.05) from control. Bars within each treatment group with different letters indicate statistically significant differences (p ≤ 0.05) across time.
FIG. 4.
Level of 2-AG in the forebrain of rat pups exposed daily from PND10 through PND16 to either corn oil (control) or 1.0, 2.5, or 5.0 mg/kg CPF. Values are expressed as nmoles/g tissue ± SE (n = 6-8). Percent inhibition for each treatment group compared with its respective control is presented in the oval overlaying the corresponding bar. Bars indicated with an asterisk (*) are statistically significant (p ≤ 0.05) from control.
dIsCussIon
The level of inhibition of enzyme activities of ChE, FAAH, and MAGL at 4 h following the last administration of CPF was in agreement (within 5%) with our previous data (Carr et al., 2011) . The present results indicate that during repeated developmental CPF exposure, the inhibition of endocannabinoid metabolism leads to elevation of endocannabinoid levels in the brain. In addition, our results confirm our previous observations that FAAH activity appears to be a much more sensitive target for CPF-mediated inhibition than ChE activity, whereas MAGL activity is less sensitive than ChE activity.
The pattern of recovery following inhibition of ChE, MAGL, and FAAH differed between the three enzymes. It is known that ChE activity in developing rats recovers faster than that of adults following exposure to CPF (Pope et al., 1991) . However, starting at the time of peak inhibition for the enzymes, the amount of recovery that had occurred by the next sampling time suggests that FAAH activity recovers much more rapidly than ChE or MAGL. This faster rate of recovery could possibly suggest that the rate of reactivation of inhibited FAAH is much faster than that of the other enzymes. However, it is unclear whether reactivation of OP-inhibited FAAH occurs as we could find no studies documenting this. Conflicting results have been reported following carbamylation of FAAH by the carbamate URB597. The reactivation of the carbamylated FAAH has been shown to be very slow (Wyffels et al., 2010) or not to occur at all (Ahn et al., 2007) . It could also be that the rate of de novo synthesis of FAAH is greater than that of the other enzymes. Similarly, it is not known whether the faster recovery of ChE in developing rats is the result of faster reactivation or increased de novo synthesis.
The changes in AEA levels following CPF treatments paralleled the pattern of inhibition and recovery of FAAH activity suggesting a direct correlation. This was further suggested by the fact that in our FAAH activity assay, the hydrolysis of AEA was almost completely eliminated in the presence of the specific FAAH inhibitor URB597 that we used to correct for non-FAAH hydrolysis. In contrast, the changes in 2-AG levels did not appear to directly follow the pattern of inhibition and recovery of MAGL activity because the inhibition of MAGL was fairly constant across time. We have previously reported that only ~45% of 2-AG hydrolysis is due to the action of MAGL in preweanling rats (Carr et al., 2011) compared with the ~85% observed in adult mice (Blankman et al., 2007) . Thus, the inhibition and recovery of another enzyme may account for the pattern of the increase and decrease of 2-AG levels that was observed in this study. The two most obvious candidate enzymes are ABHD6 and ABHD12 because they have previously been reported to degrade 2-AG (Blankman et al., 2007) ; however, these hydrolases are not sensitive to inhibition by CPF-oxon in vivo (Nomura et al., 2008) , indicating that other enzymes may be involved. Of interest, the pattern of the increase and decrease of 2-AG levels actually appeared to follow the pattern of inhibition and recovery of FAAH activity, with the peak occurring at 12 h in both parameters. Unfortunately, we did not include URB597 in our 2-AG hydrolysis assay, which would have allowed us to determine the contribution of FAAH to 2-AG hydrolysis.
With respect to the lowest dosage tested, there were no significant effects on ChE activity, MAGL activity, and 2-AG levels 24 h following the last administration of CPF. However, significant inhibition of FAAH activity and elevation of AEA was still present. Hypothetically, this suggests that if daily exposure to low levels of CPF was occurring, FAAH activity and AEA
FIG. 5.
Level of AEA in the forebrain of rat pups exposed daily from PND10 through PND16 to either corn oil (control) or 1.0, 2.5, or 5.0 mg/kg CPF. Values are expressed as pmoles/g tissue ± SE (n = 6-8). Percent inhibition for each treatment group compared with its respective control is presented in the oval overlaying the corresponding bar. Bars indicated with an asterisk (*) are statistically significant (p ≤ 0.05) from control. Bars within each treatment group with different letters indicate statistically significant differences (p ≤ 0.05) across time. levels would not have the opportunity to return to control levels, and the exposure would result in a persistent cyclic pattern of elevated AEA levels. In addition, it is possible that if the dosage of CPF was reduced to an extent where there was no significant inhibition of ChE at any time, significant effects on FAAH activity and AEA levels could still be observed. We plan additional studies to verify this assumption.
It has been reported that the levels of AEA and FAAH expression in brain gradually increase during postnatal development reaching a maximum in adulthood Morozov et al., 2004) . In contrast, 2-AG levels develop embryonically and peak shortly after birth but stabilize to adult levels during the early postnatal period (Anavi-Goffer and Mulder, 2009; Berrendero et al., 1999; Fride, 2008; Morozov et al., 2004) . The basis for the age-dependent changes in the levels of these endocannabinoids is not clear, but the postnatal increase in AEA levels and FAAH activity parallels the pattern of neuronal maturation (Morozov et al., 2004) . Thus, OP-induced inhibition of FAAH and the subsequent elevation of AEA during this period of neuronal maturation could alter that maturation process. In addition, the inhibition of FAAH could potentially alter the levels of other FAAH substrates such as the fatty acid amides oleoylethanolamide and palmitoylethanolamide, and this may have effects as well. It must also be considered that the levels of AEA differ in different regions of the brain (Bisogno et al., 1999) , and the forebrain preparation that we used in this study included regions of high and low concentration of AEA. Thus, the inhibition of FAAH and the level of accumulation of AEA in specific brain regions may actually be even higher than what is observed in our forebrain preparation. The identification of the specific brain regions affected and the magnitude of change in each region could provide significant insight into predicting the long-term neurological outcome of a low-level developmental OP exposure.
The endocannabinoid system is a major neuromodulatory system that controls emotion and anxiety (Moreira and Lutz, 2008; Taber and Hurley, 2009) . It is known that activation of the endocannabinoid system during development through exposure to exogenous cannabinoids leads to longterm effects on anxiety-related behaviors in adults (Jiang et al., 2005; O'Shea et al., 2006) . Exposure to several OP insecticides, including CPF, also has been shown to alter anxiety-like behavior and emotionality in adult animals (Aldridge et al., 2005a; Ricceri et al., 2006; Roegge et al., 2008; Timofeeva et al., 2008b; Venerosi et al., 2008 Venerosi et al., , 2010 . In addition, a previous study reported that repeated exposure of adolescent rats to URB597 resulted in changes in the levels of CB1 receptors in the adult brain (Marco et al., 2009) . This verified that inhibition of endocannabinoid degradation during development can result in long-term effects. In a more recent study from the same laboratory, exposure of adolescent mice to URB597 increased anhedonia in adults (Macrì et al., 2012) . Interestingly, this is a behavior observed in adult rats exposed postnatally to several OP insecticides (Aldridge et al., 2005a; Roegge et al., 2008) . Taken together, these reports suggest that inhibition of FAAH activity may be a potential mechanism of toxic action following low-level OP exposure. By demonstrating that developmental OP exposure leads to the elevation of endocannabinoids in the brain, this article further supports this hypothesis.
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